Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SCALE KIDS
- Sponsors Novo Nordisk
- 07 Sep 2023 Planned End Date changed from 18 Jan 2024 to 15 Jan 2027.
- 07 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Feb 2023 Status changed from active, no longer recruiting to recruiting.